Table 1.
Baseline characteristics of the studies included for analysis.
| Study | Year | Intervention | Intervention/placebo (n) | Mean age | Study duration (years) | ASCVD/MRF (%) Intervention arm (entire cohort) |
HF (%) | Primary endpoint | CV death status |
|---|---|---|---|---|---|---|---|---|---|
| EMPA KIDNEY (10) | 2022 | Empagliflozin | 1,525/1,515 | 63.9 ± 13.9 | 2.0 | 26.1/73.9 | NR | Kidney disease progression or cardiovascular death | Other secondary outcomes |
| EMPAREG (5) | 2015 | Empagliflozin | 4,645/2,323 | 63.0 ± 8.6) | 3.1 | 99.5/0.5 | 9.9 | 3-P MACE | Primary component |
| EMPEROR PRESERVED (8) | 2021 | Empagliflozin | 1,466/1,472 | 70.9 ± 9.0 | 2.1 | 36/64 | 100 (heart failure with preserved ejection fraction [HFpEF]) | CV death or hHF | Primary component |
| EMPEROR REDUCED (9) | 2022 | Empagliflozin | 927/929 | 67.6 ± 11.6 | 1.3 | 52.8/47.2 | 100 (heart failure with reduced ejection fraction [HFrEF]) | CV death or hospitalization due to worsening HF | Primary component |
| DECLARE TIMI-58 (6) | 2019 | Dapagliflozin | 8,582/8,578 | 63.9 + 6.8 | 4.2 | 40.5/59.5 | 9.9 | 3-P MACE and CV death or hHF | Primary component |
| DAPA-HF (11) | 2019 | Dapagliflozin | 1,075/1,064 | 66.2 + 11.0 | 1.5 | 55.5/36.1 [unknown: 8.4] |
100 (HFrEF) | CV death or hospitalization due to worsening HF | Primary component |
| DAPA-CKD (13) | 2020 | Dapagliflozin | 1,455/1,451 | 61.8 ± 12.1 | 2.4 | 37.8/62.2 | 10.9 | Renal composite or CV death | Primary component |
| DELIVER (12) | Dapagliflozin | 1,578/1,572 | 2.3 | NR | 100 (HFpEF) | CV death or hospitalization due to worsening HF | Primary component | ||
| CANVAS (7) | 2017 | Canagliflozin | 5,795/4,347 | 63.2 + 83 | 3.6 | 64.8/35.2 | 13.9 | 3-P MACE | Primary component |
| CREDENCE (14) | 2019 | Canagliflozin | 2,202/2,199 | 62.9 ± 9.2 | 2.6 | 50.5/49.5 | 14.9 | Renal composite or CV death | Primary component |
| VERTIS-CV (16) | 2020 | Ertugliflozin | 5,499/2,747 | 64.4 ± 8.1 | 3.5 | 100 | 23.4 | 3-P MACE | Key secondary outcome |
| SOLOIST-WHF (17) | 2121 | Sotagliflozin | 608/614 | 69 (median) | 0.75 | NR [ASCVD was an exclusion criterion] | 79.1 | CV death or hospitalization due to worsening HF | Secondary endpoint |
| SCORED (18) | 2021 | Sotagliflozin | 5,292/5,292 | 69 (Median) | 1.3 | 11.5/88.5 | 31 | CV death or hospitalization due to worsening HF | Major secondary endpoint |